Mycophenolate Mofetil

[SDL] Mycophenolate Mofetil Capsule 250 mg

[SDL] Mycophenolate Mofetil Infusion 500 mg

[SDL] Mycophenolate Mofetil Tablet 500 mg

[SDL] Mycophenolate Mofetil Oral Suspension 1,000 mg/5 mL

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

01/09/2020 Mycophenolate mofetil for immunosuppression

The MOH Drug Advisory Committee has recommended to:

• Reclassify mycophenolate mofetil 250 mg capsule and 500 mg tablet from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and

• List mycophenolate mofetil 500 mg powder for solution for infusion on the SDL

in view of favourable cost effectiveness compared to other immunosuppressants at the prices proposed by the manufacturer.

Subsidy status

[R] SDL subsidy will apply for induction and maintenance treatment of active lupus nephritis and for all registered indications of mycophenolate mofetil in Singapore:

• Prophylaxis of acute organ rejection and treatment of refractory organ rejection in patients receiving allogeneic renal transplants,

• Prophylaxis of acute organ rejection and increased graft and patient survival in patients receiving allogeneic cardiac transplants, and

• Prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration